OAβ test can be used for the early detection of Alzheimer’s Disease from a small blood sample.

Alzheimer's disease

Alzheimer’s Disease (“AD”) is perhaps the most significant neurodegenerative disease which accounts for roughly 70% of what is commonly referred to as dementia.

It is brought on gradually and progressively worsens. In 2015, there was a new dementia diagnosis every 3 seconds. In 2015, it is believed that a total of 150 million people will have dementia. Dementia, including AD, is #5 on the WHO list of “Top 10 Causes of Death,” and brings a tragic ending to so many individuals annually.

<Types of Dementia by Percentage>
71.3% Alzheimer's disease 16.9% Vascular dementia 3.4% Lewy body dementia- Parkinson's disease 0.9% Alcohol-related dementia 1.0% Frontotemporal dementia 6.5% Other types
(Ministry of Health and Welfare)

The need for early diagnosis

<Cognition for each dementia stage>

Due to the fact that there has still yet to be a cure for AD, and that lost cognitive function cannot be restored, the best way to manage AD is the delay of its onset through early diagnosis followed by preemptive care.

Early diagnosis biomarker: Beta-amyloid oligomers

  • <Monomer>
  • <Oligomers>
  • <Fibrills>
  • <Plaque>

Beta-amyloid is known to be the main player in the pathology of AD. Proteins, such as beta-amyloid, that exist within the human body, can form aggregate compounds called oligomers. Beta-amyloid oligomers ultimately form insoluble amyloid plaque, which eventually causes brain damage, followed by AD.

OAβ Test:
The first ever AD blood test

OAβ Test from PeopleBio is the only blood test currently available that can measure the oligomerization levels of beta-amyloid, the biomarker of AD, prior to the onset of symptoms. The key difference between OAβ Test and other tests available on the market is that OAβ can selectively detect beta-amyloid oligomers.

OAβ Test Automated System

OAβ Test Automated System is an automated machine for measuring the oligomerization levels of beta-amyloid in individuals suspected of having AD.


  • Automatic quantitative and qualitative assay calculation and analysis of the result data
  • Fully automated immunoassay system
  • Zero carry-over by using disposable tips for liquid handling
  • Level sensing for samples, reagents and washing solutions
  • Serial pipetting to optimize the speed of the assay
  • 8 manifold needles for fast washing
  • Simple and intuitive User Interface
  • Meticulous temperature control up to 42℃
Sample Capacity 80 Patient Sample Positions
Reagent Capacity 6 Custom Reagent Positions
Test Tube Standard 13, 16mm diameter (Customizable)
Number of Microplates 1
Well-tracking Independent well tracking & timing
System Architecture Universal Open Platform (Qualitative and Quantitative)
Sample Tray Easy loading and unloading of samples
Dimension 650 x 830 x 650mm
Power 100 - 240 V, 50-60 Hz
ELISA Reader Specifications
Dynamic Range 0 - 1,000,000 RLU
Photometer Luminometer
Filter Slots 6
Manifold Configuration 8 channels
Dispense-volume Range 100-300μl
Washing Tank 2 External Washing Tanks and 2 Waste Tanks
Wash Cycle 1 - ∞ (Customizable)
Residual Volume <1μl
Temperature Range Up to 42°C
Temperature Uniformity ±0.5°C
Shaking Amplitude: 1 mm, Speed: Up to 800 RPM
Temperature Monitoring Yes
Aspiration Volume >5μl
Tip Disposable
Serial Dilution Yes
Replicates Yes
Precision <0.8% CV at 100 μl
Work Protocols (Assays) Unlimited
Data Processing Quantitative and Qualitative
Access Level Control Yes (Master, Manager, and Operator)
O/S Windows XP, 7, and 10